Speckle-type POZ (pox virus and zinc finger protein) protein (SPOP) is a cullin 3-based E3 ubiquitin ligase adaptor protein that plays a crucial role in ubiquitin-mediated protein degradation. Recently, SPOP has attracted major research attention as it is frequently mutated in a range of cancers, highlighting pleiotropic tumorigenic effects and associations with treatment resistance. Structurally, SPOP contains a functionally critical N-terminal meprin and TRAF homology (MATH) domain for many SPOP substrates. SPOP has two other domains, including the internal Bric-a-brac-Tramtrack/Broad (BTB) domain, which is linked with SPOP dimerization and binding to cullin3, and a C-terminal nuclear localization sequence (NLS). The dysregulation of SPOP-mediated proteolysis is associated with the development and progression of different cancers since abnormalities in SPOP function dysregulate cellular signaling pathways by targeting oncoproteins or tumor suppressors in a tumor-specific manner. SPOP is also involved in genome stability through its role in the DNA damage response and DNA replication. More recently, studies have shown that the expression of SPOP can be modulated in various ways. In this review, we summarize the current understanding of SPOP’s functions in cancer and discuss how to design a rational therapeutic target.
Triple-negative breast cancer (TNBC) is a type of breast tumor that currently lacks options for targeted therapy. Tremendous effort has been made to identify treatment targets for TNBC. Here, we report that the expression level of anaphase promoting complex (APC) coactivator Cdh1 in TNBC is elevated compared to that in the adjacent healthy tissues, and high levels of Cdh1 expression are correlated with poor prognoses, suggesting that Cdh1 contributes to the progression of TNBC. Interfering with the function of Cdh1 can potentiate the cytotoxic effects of PARP inhibitors against BRCA-deficient and BRCA-proficient TNBC cells through inducing DNA damage, checkpoint activation, cell cycle arrest, and apoptosis. Further investigation reveals that Cdh1 promotes BRCA1 foci formation and prevents untangled DNA entering mitosis in response to PARP inhibition (PARPi) in TNBC cells. Collectively, these results suggest that APC/Cdh1 is a potential molecular target for PARPi-based therapies against TNBCs.
Background: Evaluation of tumor efficacy is central to cancer care. Progression‐free survival (PFS) is widely used as an early surrogate for treatment effectiveness, but more timely and reliable biomarkers are needed. Early tumor shrinkage (ETS) and depth of response (DpR) have emerged as promising predictors: ETS reflects early treatment sensitivity at first radiologic assessment, whereas DpR quantifies the maximum tumor reduction and may capture the durability of benefit. Methods: We conducted a narrative synthesis of clinical studies assessing ETS and/or DpR across solid tumors, focusing on their definitions, measurement under RECIST, and associations with PFS and overall suvival (OS). We also summarized advances in imaging and multidimensional assessment framworks that could improve the accuracy and clinical utility of these indicators, and highlighted sources of heterogeneity and current gaps. Results: Across multiple retrospective and post‐hoc analyses, ETS provides an early signal that identifies patients more likely to benefit from therapy and can inform treatment adaptation. DpR shows consisten correlations with long‐term outcomes and complements PFS by reflecting the magnitude of tumor control. Both ETS and DpR demonstrate predictive value for PFS and OS; however, variability in cut‐offs (e.g., ETS 20%–30%), timing of assessments, tumor types, and treatment modalities limits comparability. Emerging imaging technologies and composite response frameworks offer opportunities to enhance measurement precision and reproducibility. Conclusions: ETS and DpR are promising, clinically interpretable markers for monitoring treatment effcacy and prognosis. Standardized definitons, prospective validation, and integration with molecular and imaging biomarkers (e.g., ctDNA, radiomics, and machine—learning—enhanced imaging) are needed to refine their application and solidify their role in routine cancer therapy monitoring.
Dysregulation of Speckle-type POZ protein (SPOP) and cargo receptor p62/SQSTM1 impairs homologous recombination (HR)-mediated DNA repair by destabilizing RAD51 and FLNA, yet their mechanistic interplay in genomic stability and oncogenesis remains unclear. In this study, we found that the interaction between SPOP and p62/SQSTM1 is obviously enhanced in nucleus in response to DNA damage. Moreover, the nuclear ubiquitination of p62/SQSTM1 at lysine 7 by SPOP led to its degradation, resulting in upregulation of RAD51 and FLNA, RAD51 foci formation, and HR efficiency. In addition, patients-derived p62/SQSTM1 mutations in SPOP-binding consensus (SBC) motif (S276Y/S277G/S277I) increased radiotherapy sensitivity in vitro and in vivo, which attributes to HR deficiency caused by increased degradation of RAD51 and FLNA proteins, and decreased RAD51 and γ-H2AX foci formation. Our finding provides insight into the regulation of HR by SPOP and p62/SQSTM1, and disrupting the interaction between SPOP, p62/SQSTM1 and nuclear ubiquitination may be a potential approach for overcoming radiotherapy resistance in cancer.
WD repeat and HMG-box DNA-binding protein 1 (WDHD1) has been identified as a crucial oncogene in various tumors, but its role in pancreatic cancer remains unexplored. This study investigated the mechanisms by which WDHD1 contributes to pancreatic cancer progression. Differential analysis of the Cancer Genome Atlas (TCGA) pancreatic cancer samples identified abnormally expressed genes. Cellular assays, including cell proliferation, flow cytometry, and apoptosis assays, demonstrated WDHD1’s oncogenic role. WDHD1 expression was significantly elevated in pancreatic cancer cells and tissues compared to normal counterparts. Knockdown of WDHD1 inhibited cell proliferation, induced apoptosis, and caused G1-phase cell-cycle arrest. In vivo xenograft models further validated that WDHD1 knockdown suppressed the growth of pancreatic cancer cells. Mechanistically, WDHD1 knockdown resulted in significant reductions in CDK4 and cyclin D1 protein levels, whereas WDHD1 overexpression produced the opposite effects. Additionally, E2F1 overexpression increased the expression of WDHD1 at both mRNA and protein levels. Rescue experiments revealed that WDHD1 knockdown could reverse the E2F1-induced upregulation of CDK4 and cyclin D1 protein levels. In conclusion, E2F1 promotes pancreatic cancer cell proliferation and cell-cycle progression by upregulating WDHD1, which in turn enhances the expression of the CDK4–cyclin D1 complex.